Treatment Approach for MSI-H/dMMR CRC


 

ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Study: Atezo Monotherapy vs. mFOLFOX6/Bevacizumab/Atezo in the 1L Treatment of dMMR/MSI-H mCRC

1,075 views
June 9, 2022
0 Comments
Login to view comments. Click here to Login
Treatment Approach for MSI-H/dMMR CRC